Serum adipokines in inflammatory bowel disease

Table 1 Subject characteristics

	Crohn’s disease (n = 24)	Ulcerative colitis (n = 16)	Control group (n = 16)	P value
Female, %	54	56	50	0.902
Age, yr	31.0 ± 9.4	33.2 ± 21.9	30.3 ± 12.2	0.060
BMI, kg/m2	21.4 ± 2.8	23.4 ± 5.6	22 ± 4.8	0.444
Waist circumference, cm	78.8 ± 9.9	78.4 ± 15.7	78.5 ± 8.5	0.090
Hip circumference, cm	91.5 ± 8.8	93.6 ± 11.9	91.1 ± 8.1	0.345
Waist/hip ratio	0.86 ± 0.08	0.84 ± 0.08	0.86 ± 0.07	0.472
Duration of IBD, yr	9.5 ± 7.9	10.5 ± 8.1	-	0.105
Activity of IBD			-
CDAI	A: 241 ± 155	-
	B: 36.6 ± 25.3
Montreal severity classification
S0/S1/S2/S3	-	A: 0/1/14/1
		B: 8/8/0/0
Vienna classification		-	-
A1/A2	21/3
L1/L2/L3/L4	2/5/17/0
B1/B2/B3	14/6/4

A: Before treatment; B: 3 mo after initiation of treatment; CDAI: Crohn’s disease activity index; IBD: Inflammatory bowel disease; BMI: Body mass index.

Table 2 Serum adipokine concentrations

	Adiponectin, μg/mL	Leptin, ng/mL	TGF-β1, pg/mL	Chemerin, ng/mL	Resistin, ng/mL	Visfatin, ng/mL
Crohn’s disease
Before treatment (n = 24)	14.7 ± 19.4	8.0 ± 9.1a	3152 ± 1137	418 ± 193	19.3 ± 12.5a	23.2 ± 3.2a
Upon treatment (n = 24)	11.7 ± 6.7	14.9 ± 15.1c	3261 ± 1327	344 ± 127	17.9 ± 13.2a	20.4 ± 4.8ac
Ulcerative colitis
Before treatment (n = 16)	9.8 ± 4.1	8.6 ± 6.3a	4378 ± 361	421 ± 214	23.2 ± 11.0a	18.8 ± 5.3a
Upon treatment (n = 16)	13.7 ± 5.3	9.2 ± 7.3	2877 ± 1761	379 ± 208	14.5 ± 4.0c	21.0 ± 3.5a
Control group
Healthy subjects (n = 16)	9.3 ± 3.0	16.5 ± 10.1	3027 ± 809	355 ± 69	10.7 ± 1.1	14.1 ± 5.4

^aP < 0.05 vs control group;

^cP < 0.05 vs before treatment. TGF: Tumor growth factor.

Table 3 Results of correlational analyses (P values) between adipokine levels and clinical parameters

Adipokine level	A/B	Severity, points	Duration of IBD, yr	Age, yr	Waist circumference, cm	Hip circumference, cm	BMI, kg/m2
Crohn’s disease
TGF-β1	A	0.157	0.068	0.067	0.061	0.126	0.065
	B	0.235	0.065	0.468	0.084	0.068	0.056
Adiponectin	A	0.086	0.055	0.065	0.171	0.096	0.116
	B	0.056	0.054	0.058	0.061	0.085	0.075
Leptin	A	0.274	0.118	0.065	0.076	0.074	0.085
	B	0.065	0.086	0.081	0.070	0.085	0.268
Chemerin	A	0.066	0.129	0.063	0.088	0.115	0.095
	B	0.149	0.097	0.224	0.183	0.093	0.085
Resistin	A	0.065	0.066	0.080	0.061	0.116	0.063
	B	0.159	0.129	0.056	0.078	0.075	0.069
Visfatin	A	0.094	0.076	0.159	0.127	0.097	0.061
	B	0.085	0.085	0.054	0.075	0.087	0.105
Ulcerative colitis
TGF-β1	A	0.068	0.061	0.137	0.082	0.154	0.054
	B	0.073	0.137	0.193	0.156	0.954	0.068
Adiponectin	A	0.065	0.060	0.061	0.067	0.177	0.061
	B	0.106	0.070	0.070	0.090	0.095	0.271
Leptin	A	0.093	0.080	0.060	0.086	0.158	0.081
	B	0.085	0.056	0.071	0.080	0.085	0.224
Chemerin	A	0.065	0.052	0.088	0.075	0.173	0.101
	B	0.077	0.130	0.093	0.088	0.055	0.094
Resistin	A	0.064	0.060	0.061	0.073	0.084	0.070
	B	0.084	0.068	0.080	0.062	0.275	0.260
Visfatin	A	0.065	0.079	0.060	0.079	0.054	0.161
	B	0.115	0.069	0.070	0.117	0.064	0.070

A: Before treatment; B: 3 mo after initiation of treatment; BMI: Body mass index; IBD: Inflammatory bowel disease; TGF: Tumor growth factor.